Lilly Acquires AtaiBeckley in Multibillion Deal
Lilly Acquires AtaiBeckley, adding rapid-acting neuroplastogens including BPL-003; the news sent AtaiBeckley shares sharply higher and shifted biotech flows.
KEY TAKEAWAYS
- Lilly agreed to acquire AtaiBeckley, gaining its rapid-acting neuroplastogen portfolio centered on BPL-003.
- Secondary reports set deal value from $2.8 billion to up to $3.8 billion.
- BPL-003 has FDA Breakthrough Therapy designation and a phase-3 program slated in Q2 2026.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Eli Lilly and Company (NYSE: LLY) announced on July 16, 2026, it will acquire AtaiBeckley Inc. (Nasdaq: ATAI) in a multibillion-dollar deal to add rapid-acting neuroplastogens to its neuroscience pipeline.
Deal Terms and Valuation
The companies issued a joint press release confirming a definitive agreement for Lilly to acquire AtaiBeckley. The transaction is subject to customary closing conditions, including regulatory approvals and AtaiBeckley shareholder consent.
Secondary reports valued the deal between $2.8 billion and up to $3.8 billion. The press release did not specify the amount. AtaiBeckley shares rose about 50% premarket on July 16, 2026, at 6:36 a.m. ET following reports of the acquisition.
Pipeline Expansion for Depression
Lilly said the acquisition expands its neuroscience pipeline to advance therapies for treatment-resistant depression and other mental health conditions. The deal transfers full ownership of AtaiBeckley’s portfolio of rapid-acting neuroplastogens to Lilly.
AtaiBeckley was formed by merging atai Life Sciences and Beckley Psytech, combining clinical-stage programs including VLS-01 for treatment-resistant depression, EMP-01 for social anxiety disorder, and a discovery portfolio of 5-HT2A receptor agonists and non-hallucinogenic neuroplastogens.
BPL-003 Clinical Status
The lead program, BPL-003, is an intranasal formulation of 5-MeO-DMT designed to provide durable relief from treatment-resistant depression. It has received Breakthrough Therapy designation from the U.S. Food and Drug Administration.
AtaiBeckley had planned a phase 3 trial for BPL-003 starting in the second quarter of 2026, following positive phase 2b results and a $150 million fundraising round.
The acquisition gives Lilly ownership of a slate of rapid-acting candidates for mood and anxiety disorders, strengthening its neuroscience portfolio as it seeks to diversify beyond obesity and diabetes treatments.
